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An antiserum raised against the purified human erythrocyte glucose transporter specifically 
immunoprecipitated a major protein of Mr 36000 and a minor protein of iW, 58000 from human pancreatic 
islets. The biosynthetic incorporation of [35S]methionine into the 36kDa protein increased 2-3-fold in 
16 mM D-glucose with 0.1 mM IBMX as compared to islets incubated in 3 mM D-glucose either with or 
without IBMX. D-Glucose tested without or with IBMX had no effect on the biosynthesis of the 58-kDa 
protein. The 36-kDa protein was also detected in rat islets and rat islet tumor cells. It is suggested that 
this protein may represent a D-glucose and CAMP sensitive component of a glucose transport or glucose 
binding protein in the pancreatic @-cell. 
Human erythrocyte glucose transporter Human pancreatic islet Glucose transport 
Glucose regulation 3-Isobutyl-I-methylxanthine 
~-Cell protein 
1. INTRODUCTION 
A prominent function of the pancreatic B-cell is 
to synthesize and release insulin in response to D- 
glucose. B-Cells have been. found to take up D- 
glucose by facilitated diffusion utilizing a 
stereospecific glucose transport system [l]. Ex- 
periments with phlorizine, its aglycone phloretin 
[2-41 and cytochalasin B [5], showed that binding 
of these compounds to B-cells not only inhibited 
D-glucose transport, but also affected the release 
of insulin. This has been interpreted to support the 
regulator site model for the effect of D-glucose on 
Abbreviations: NCS, newborn calf serum; HS, human 
serum; IBMX, 3-isobutyl-1-methylxanthine; FCS, foetal 
calf serum; HEPES, N-hydroxy-ethyl-piperazine-N- 
2-ethane-sulfonic acid; PMSF, phenylmethylsulfonyl- 
fluoride; PCMBS, p-chloromercuribenzenesulfonic 
acid; SDS, sodium dodecylsulfate; CAMP, cyclic adeno- 
sine 3 ’ ,5 ’ -monophosphate 
insulin biosynthesis and release, envisaging that 
the binding of D-glucose to a hypothetical mem- 
brane receptor mediates a signal to the cell [6]. 
However, substantial experimental evidence favors 
an alternative hypothesis, the substrate site model 
[6], in which a signal is generated from the 
metabolism of D-glucose to act as a trigger for in- 
sulin biosyntheses and release. In this model the 
glucose sensor is the enzyme(s) catalysing a rate- 
limiting step in glucose metabolism, for instance a 
kinase catalyzing the phosphorylation of the sugar 
[7]. A dual-site mechanism in which glucose in- 
teraction at the membrane as well as its metab- 
olism within the cell play a role has been suggested 
to explain available experimental results [8]. The 
molecular components involved in the uptake and 
triggering effect of D-glucose are yet to be iden- 
tified and it remains to be determined whether D- 
glucose stimulates the biosynthesis of proteins 
other than (pro)insulin. We have used an anti- 
serum raised against the purified human erythro- 
cyte glucose transporter [9] to determine whether 
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immunologically cross-reactive proteins are pre- respectively, in the same type of medium at 16 mM 
sent in islet cells. It is tested whether the biosyn- glucose without IBMX and substituting HS with 
thesis of such proteins is stimulated by D-glucose 2.5% FCS. In one experiment human islets were 
alone or combined with the phosphodiesterase in- labelled with [35S]cysteine (>600 Ci/mmol, Radio- 
hibitor IBMX which increases the cellular concen- chemical Centre, Amersham) in addition to 
tration of CAMP in the B-cells and thereby [3SS]methionine in order to obtain radioactive 
enhances glucose-induced insulin release [ 10,111. labelling of human proinsulin and insulin. 
2. MATERIALS AND METHODS 
The antiserum against the human erythrocyte 
glucose transporter [9] was generously provided by 
Drs D.C. Sogin and P. Hinkle. Monoclonal an- 
tibody against HLA-A,B,C antigens (W6/32) was 
obtained from Sera Labs. (Sussex). Insulin an- 
tibodies against purified porcine insulin were rais- 
ed in guinea pigs. 
Human islets of Langerhans were isolated [12] 
from the pancreas of 5 cadaver kidney donors, 3 
males and 2 females, ranging between 19-36 years 
of age. Portions of pancreas (-2-3 g) were 
digested with collagenase. After washing the digest 
by centrifugation, islets were individually selected 
under a stereomicroscope. The islets were cultured 
at 37’C for 1 day in RPM1 1640 supplemented 
with 10% NCS, transferred to medium in which 
NCS was replaced by 0.5% HS and finally cultured 
for l-7 days. The release of insulin was determin- 
ed by radioimmunoassay. 
Rat islets were isolated from the pancreas of 
male Wistar rats by collagenase digestion followed 
by Ficoll (Pharmacia, Uppsala) gradient cen- 
trifugation [ 131. 
Cells were prepared from a transplantable rat in- 
sulinoma [ 141 in Hanks balanced salt solution con- 
taining 1% bovine serum albumin and separated 
from erythrocytes by centrifugation (10 min, 
500 x g) on Ficoll-Paque (Pharmacia). 
After labelling, islets or cells were washed twice 
by centrifugation (islets, 30 s 150 x g; cells, 5 min 
50 x g) in medium containing 5 mM L-methionine 
and once in 10 mM Hepes (pH 7.4) containing 
150 mM NaCl, 5 mM methionine and 2 mM 
PMSF and then lysed in the same buffer contain- 
ing 2000 KIE/ml trasylol, 0.1 mM PCMBS, 5 mM 
EDTA, 5 mM iodoacetamide and 1% NP-40. 
Islets were frozen and thawed once and then kept 
on ice for an additional 30 min before the lysate 
was centrifuged for 30 min at 100000 x g. The 
supernatant was incubated at 4°C for 1 h with 
10 pl normal rabbit serum/100 ~1 supernatant, 
followed by adsorption to an excess of protein 
A-Sepharose CL4B (Pharmacia) before im- 
munoprecipitation with immune serum. Aliquots 
(lOO,ul, l-2 x 10’ cpm) of pre-absorbed lysate 
were incubated with 20~1 immune serum or nor- 
mal serum for 16 h followed by incubation for 
30 min at 4°C with 100 ~1 pre-swollen protein 
A-Sepharose. The protein A-Sepharose anti- 
body-antigen complex was washed 5 times by cen- 
trifugation in 10 mM Hepes buffer containing 
150 mM NaCl, 2 mM PMSF and 0.5% NP-40 (pH 
7.4) and once in cold re-distilled water. Immune 
complexes were analysed by SDS-polyacrylamide 
gel electrophoresis on 7.5-15% gradient or 10% 
uniform slab gels and processed for autoradio- 
graphy 1151. 
Human islets were divided into 4 aliquots 
(150-300 islets each) and transferred to 2 ml L- 
methionine-deficient RPM1 1640 medium contain- 
ing 0.5% heat inactivated and dialysed HS, 1 g/l 
NaHC03, 100 pug streptomycin/ml, 100 units 
penicillin/ml, and 0.5 mCi [“‘Slmethionine (>900 
Ci/mmol, New England Nuclear). D-Glucose was 
either 3 mM or 16 mM and the incubations were 
carried out for 20 h either in the absence or 
presence of 0.1 mM IBMX. Rat islets and rat in- 
sulinoma cells were labelled for 20 h and 6 h, 
Autoradiograms were scanned on an LKB Ultro 
Scan Laser Densitometer using a [r4C]methylated 
protein kit (Radiochemical Centre, Amersham) as 
standard to corroborate an approximate propor- 
tionality of amount of radioactivity to band 
intensity. 
3. RESULTS 
The antiserum to the human erythrocyte glucose 
transporter specifically immunoprecipitated a ma- 
jor band at MI 36000 from human islets (fig.la), 
rat islets (fig.lc) and rat insulinoma cells (fig. le). 
A faint band at MI 58000 (fig.2A,C,E,G; fig.lc) 
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Fig. 1. SDS-polyacrylamide gel electrophoresis and 
autoradiography of immunoprecipitates of human islet 
(a,b), rat islet (c,d) and rat islet tumor cell (e,f) proteins 
with antiserum against human erythrocyte glucose 
transporter (a,c,e) and normal rabbit serum (b,d,f). 
Positions of iW, markers are shown to the right. 
was immunoprecipitated from human islets as well 
as from rat islets but not from rat insulinoma cells 
(fig.le). Normal rabbit serum did not immunopre- 
cipitate those bands (fig.lb,d,f; fig.2B,D,F,H). 
Densitometric analyses of autoradiograms imi- 
lar to that in fig.2 demonstrated that the biosyn- 
thesis of the 36-kDa protein was increased after in- 
cubation with 16 mM D-glucose and 0.1 mM 
IBMX as compared to 3 mM D-glucose with 
@ < 0.01) or without IBMX (p < 0.001) (table 1). 
There was no effect of 0.1 mM IBMX at 3 mM 
D-glucose (table 1). In the absence of IBMX, the 
effect of 16 mM D-glucose varied between islets 
isolated from the 5 different donors, the individual 
values of the relative density of the 36-kDa band 
was 0.8,0.8, 1.2, 1.8 and 2.6, respectively. No dif- 
ference was found in the density of the faint 
58-kDa protein band. 
In lysates of human islets labelled with 
[%]methionine for 20 h, the total trichloroacetic 
acid-precipitable counts were increased by 17% 
and 22%, respectively, in islets incubated without 
or with 0.1 mM IBMX at 16 mM glucose as com- 
Fig.2. SDS-polyacrylamide gel electrophoresis and 
autoradiography of immunoprecipitates of human islet 
cell proteins with antiserum against human erythrocyte 
glucose transporter (A,C,E,G) and normal rabbit sera 
(B,D,F,H). Islets were biosynthetically labelled for 20 h 
with [35S]methionine in the presence of 3 mM glucose 
(A,B), 16 mM glucose (CD), 3 mM glucose + 0.1 mM 
IBMX (E,F) and 16 mM glucose + 0.1 mM IBMX 
(G,H). Positions of M, markers are shown to the right. 
pared to islets incubated at 3 mM glucose. The ef- 
fect of glucose and IBMX on class I major histo- 
compatibility antigens (HLA-A,B,C) [ 151 biosyn- 
thesis was also investigated and compared to that 
of proinsulin and insulin. HLA-A,B,C antigens 
were immunoprecipitated by the monoclonal an- 
tibody W6/32 and (pro)insulin was immuno- 
precipitated by a guinea pig antiserum against por- 
cine insulin from human islets labelled for 20 h in 
the presence of 3 mM or 16 mM D-glucose with or 
333 
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Table 1 
Relative amounts of the 36-kDa antigen 
immunoprecipitated by anti-erythrocyte glucose 
transporter 
D-Glucose IBMX n Relative 
(mM) (mM) amount 
3.0 0 5 1 
16.0 0 5 1.4 f 0.9 
3.0 0.1 5 1.1 f 0.4 
16.0 0.1 5 2.4 f 0.2a 
’ The effect of D-glucose with IBMX was different from 
that at 3 mM D-glucose both without @ < 0.001) and 
with IBMX @ c 0.01) (paired Student’s t-test) 
Results are shown as mean f SD for the no. expt. (n) 
without 0.1 mM IBMX. Densitometric analyses of 
autoradiograms showed no effect of D-glucose 
whether IBMX was present or not, on the biosyn- 
thesis of either the 44-kDa heavy chain or the 
12.5kDa,&-microglobulin light chain of the HLA- 
A,B,C antigens. The autoradiographic density of 
the proinsulin band was increased about 4-fold in 
islets labelled at 16 mM D-glucose as compared to 
3 mM D-glucose. IBMX slightly enhanced the den- 
sity of the proinsulin band at 16 mM D-glucose. 
The broad appearance of the band corresponding 
to insulin did not permit accurate densitometric 
analyses. The release of insulin during 20 h incuba- 
tion was 0.4 and 1.04 ng/islet at 3.0 mM D- 
glucose without and with 0.1 mM IBMX, respec- 
tively. At 16 mM D-glucose the corresponding 
values were 2.69 and 3.01 ng/islet, respectively. 
4. DISCUSSION 
Antisera against he purified glucose transporter 
of human erythrocytes, which detects an Mr 55 000 
protein [9], have been used tentatively to identify 
a glucose transport protein of MI 41000 in chicken 
embryo fibroblasts [17], a protein of M, 45000 in 
rat adipocytes [18,191 and a protein of MI 55 000 in 
HeLa cells [9]. Photoaffinity labelling of the 
glucose transporter with [‘Hlcytochalasin B con- 
firmed that the transport protein has an MI of 
45 000-46000 in rat adipocytes [20,21] and chicken 
embryo fibroblasts [22], but an additional protein 
334 
component of MI 50000-52000 was also labelled 
[20,22]. 
In the present studies with human and rat islets 
it was found that the glucose transporter antiserum 
specifically immunoprecipitated a major band at 
Mr 36008 and a minor band at M, 58000. In rat 
islet tumor cells the only protein specifically 
precipitated had an MI of 36000 which indicates 
that this protein is present in insulin producing B- 
cells. 
Although the reactivity with the glucose 
transporter antisera suggest that one or both of 
these proteins share antigenic determinants with 
the human erythrocyte glucose-transport protein in 
islet cell the possibility of a cross-reacting protein 
unrelated to the transporter cannot be ruled out. 
The MI determined for those proteins is different 
from the M, determined for glucose transporter 
molecules in other cells. It is important o note that 
experiments with the same antiserum used here 
have detected components of different relative 
molecular sizes in different cells [9,18]. We 
speculate therefore that glucose transport proteins 
in different cells may not have the same relative 
molecular sizes but share similar antigenic deter- 
minants. It will be important to determine the M, 
of islet B-cell components which can be photoaf- 
finity labelled with radioactive cytochalasin B. 
Such studies are difficult to carry out with human 
islets due to the lack of sufficient material to 
prepare membranes but are in progress with the rat 
islet tumor cells. 
The stimulating effect of glucose combined with 
IBMX on the biosynthetic labelling of the 36-kDa 
protein suggest that his protein is somehow 
regulated by glucose and islet CAMP levels. It is 
also possible that the increased insulin release pro- 
motes the biosynthesis due to an increased mem- 
brane turnover during exocytosis. Recent studies 
with islet cell surface antibodies showed that 
IBMX increased the internalization of islet cell 
surface-bound antibodies [23]. 
We also found that glucose and IBMX enhanced 
the biosynthetic incorporation of [35S]cysteine into 
human proinsulin. However, no effect of glucose 
and/or IBMX was detected on the biosynthesis of 
the heavy and light chain of the class I major 
histocompatibility antigens. Although total islet 
protein synthesis was stimulated by glucose these 
data indicate that the effect of D-glucose combined 
Volume 157, number 2 FEBS LETTERS July 1983 
with IBMX does not affect aU islet proteins and 
that the biosynthesis of the 36-kDa protein is 
specifically stimulated by D-glucose. 
ACKNOWLEDGEMENTS 
We are grateful to Drs D.C. Sogin and P. Hinkle 
(Cornell University, Ithaca NY) for donating the 
antiserum against the purified human erythrocyte 
glucose transporter. We thank MS Hanne Richter 
Olesen and MS Annemette Borch for expert 
technical assistance and the staff at the Hagedorn 
Research Laboratory for assisting in the isolation 
of human islets. S.B. is the recipient of Juvenile 
Diabetes Foundation Research Fellowship. 
REFERENCES 
VI 
PI 
I31 
[41 
151 
WI 
[71 
181 
Hellman, B., Sehlin, J. and Taljedal, I.-B. (1971) 
Biochim. Biophys. Acta 241, 147-154. 
Hellman, B., Lemmark, A., Sehlin, J. and 
Taljedal, I.-B. (1972) Metabolism 21, 60-66. 
Hellman, B., Lernmark, A., Sehlin, J. and 
Tiiljedal, I.-B. (1982) Mol. Pharmacol. 8,759-769. 
Ashcroft, S.J.H. and Nino, S. (1978) Biochim. Bio- 
phys. Acta 538, 334-342. 
Lacy, P.E., Klein, N.J. and Fink, C.J. (1973) 
Endocrinology 92, 1458-1468. 
Randle, P.J., Ashcroft, S.J.H. and Gill, J.R. 
(1%8) in: Carbohydrate Metabolism and Release of 
Hormones (Dickens, F. et al. eds) ~01.1, 
pp.427-447, Academic Press, London, New York. 
Ashcroft, S.J.H. (1980) Diabetologia 18, 5-15. 
Ashcroft, S.J.H., Weerasinghe, L.C.C. and 
Randle, P.J. (1973) Biochem. J. 132, 223-231. 
[9] Sogin, D.C. and Hinkle, P.C. (1980) Proc. Natl. 
Acad. Sci. USA 77, 5725-5729. 
WI 
t111 
WI 
1131 
[I41 
1151 
1161 
[I71 
WI 
1191 
PI 
WI 
WI 
[231 
Hellman, B., Idahl, L.-A., Lernmark, A. and 
Tiiljedal, I.-B. (1974) Proc. Natl. Acad. Sci. USA 
71, 3405-3409. 
Kohnert, K.-D., Ziegler, B., Hahn von Dorsche, 
H., Hemke, B. and Schroder, D. (1982) Mol. Cell. 
Endocrinol. 28, 425-437. 
Nielsen, J.H. (1981) Acta Biol. Med. Germ. 40, 
55-60. 
Lernmark, A., Nathans, A. and Steiner, D.F. 
(1976) J. Cell Biol. 71, 606-623. 
Chick, W.L., Warren, S., Chute, R.N., Like, 
A.A., Lauris, V. and Kitchen, K.C. (1977) Proc. 
Natl. Acad. Sci. USA 74, 628-632. 
Baekkeskov, S., Kanatsuna, T., Klareskog, L., 
Nielsen, D.A., Peterson, P.A., Rubenstein, A.H., 
Steiner, D.F. and Lernmark, A. (1981) Proc. Natl. 
Acad. Sci. USA 78, 64566460. 
Gold, G., Gishizky, M.L. and Grodsky, G.M. 
(1982) Science 218, 56-58. 
Salter, D.W., Baldwin, S.A., Lienhard, G.E. and 
Weber, M.J. (1982) Proc. Natl. Acad. Sci. USA 79, 
1540-1544. 
Wheeler, T. J., Simpson, I.A., Sogin, D.C., 
Hinkle, P.C. and Cushman, S.W. (1982) Biochem. 
Biophys. Res. Commun. 105, 89-95. 
Lienhard, G.E., Kim, H.H., Ransome, K.J. and 
Gerga, J.C. (1982) Biochem. Biophys. Res. Com- 
mun. 105, 1150-1156. 
Shanahan, M.F., Olsen, S.A., Weber, M. J., 
Lienhard, G.E. and Gerga, J.C. (1982) Biochem. 
Biophys. Res. Commun. 107, 38-43. 
Pessin, J.E., Oka, Y., Oppenheimer, C.L., 
Gitomer, W., Massague, J. and Czech, M. (1983) 
J. Biol. Chem., in press. 
Pessin, J.E., Tillotsen, L.G., Yamada, K., 
Gitomer, W., Carter-Su, C., Mara, R., Isselbacher, 
K. J. and Czech, M.P. (1982) Proc. Natl. Acad. Sci. 
USA 79, 2286-2290. 
Ohgawara, H., Okono, T., Kataoka, K. and 
Sakurai, Y. (1983) Diabetologia 24, 117-121. 
335 
